Scientists from Johns Hopkins University have genetically engineered an experimental nanobody that targets alpha-synuclein protein clumps thought to be involved in the pathophysiology of Parkinson’s disease

Medical Mythbusting Commentary for August 9, 2022

Source:
Parkinson’s research: Experimental nanobody targets toxic proteins

Reference:
α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice